Premium
A Catalase‐Like Metal‐Organic Framework Nanohybrid for O 2 ‐Evolving Synergistic Chemoradiotherapy
Author(s) -
He Zhimei,
Huang Xiaolin,
Wang Chen,
Li Xiangli,
Liu Yijing,
Zhou Zijian,
Wang Sheng,
Zhang Fuwu,
Wang Zhantong,
Jacobson Orit,
Zhu JunJie,
Yu Guocan,
Dai Yunlu,
Chen Xiaoyuan
Publication year - 2019
Publication title -
angewandte chemie
Language(s) - English
Resource type - Journals
eISSN - 1521-3757
pISSN - 0044-8249
DOI - 10.1002/ange.201902612
Subject(s) - tumor hypoxia , doxorubicin , chemoradiotherapy , chemistry , nanotechnology , in vivo , radiation therapy , nanomaterials , drug delivery , nanoparticle , cancer research , materials science , chemotherapy , medicine , surgery , microbiology and biotechnology , biology
Tumor hypoxia, the “Achilles’ heel” of current cancer therapies, is indispensable to drug resistance and poor therapeutic outcomes especially for radiotherapy. Here we propose an in situ catalytic oxygenation strategy in tumor using porphyrinic metal‐organic framework (MOF)‐gold nanoparticles (AuNPs) nanohybrid as a therapeutic platform to achieve O 2 ‐evolving chemoradiotherapy. The AuNPs decorated on the surface of MOF effectively stabilize the nanocomposite and serve as radiosensitizers, whereas the MOF scaffold acts as a container to encapsulate chemotherapeutic drug doxorubicin. In vitro and in vivo studies verify that the catalase‐like nanohybrid significantly enhances the radiotherapy effect, alleviating tumor hypoxia and achieving synergistic anticancer efficacy. This hybrid nanomaterial remarkably suppresses the tumor growth with minimized systemic toxicity, opening new horizons for the next generation of theranostic nanomedicines.